多西紫杉醇化疗治疗去势抵抗性前列腺癌的疗效:单中心经验

IF 0.1 Q4 ONCOLOGY
Evren Süer, N. Hamidi, M. Gökçe, S. Baltacı
{"title":"多西紫杉醇化疗治疗去势抵抗性前列腺癌的疗效:单中心经验","authors":"Evren Süer, N. Hamidi, M. Gökçe, S. Baltacı","doi":"10.4274/UOB.821","DOIUrl":null,"url":null,"abstract":"77 ©Telif Hakkı 2017 Üroonkoloji Derneği / Üroonkoloji Bülteni Galenos Yayınevi tarafından basılmıştır Ya z›fl ma Ad re si/Ad dress for Cor res pon den ce: Dr. Nurullah Hamidi, Atatürk Eğitim ve Araştırma Hastanesi, Üroloji Kliniği, Ankara, Türkiye Tel.: +90 312 508 22 58 E-mail: dr.nhamidi86@gmail.com ORCID-ID: orcid.org/0000-0002-6825-1813 Ge liş Ta ri hi/Re cei ved: 06.02.2017 Ka bul Ta ri hi/Ac cep ted: 31.05.2017 Objective: Prostate cancer (PCa) is the second most commonly seen cancer type worldwide. Mortality due to PCa is mostly linked to the development of castration resistant PCa (CRPC). In these patients, the main treatment option is docetaxel based chemotherapy (DBC). In this study, we aimed to present our retrospective series. Materials and Methods: We retrospectively evaluated the patients who received DBC in our clinic between January 2004 and December 2015. Totally 162 patients who are histopathologically diagnosed with PCa, clinically and radiographically demonstrated metastasis and fit to European Association of Urology CRPC criteria were included to the study. DBC was given for one day for a 3-week period, with a dose of 75 mg/m2. Prostate specific antigen (PSA) response is evaluated for ≥50% decrease in the PSA level measured at the first day of the chemotherapy. Additionally, overall survival is evaluated. Results: The majority of the patients had high stage and high Gleason score PCa. Of them totally 76% were a primary metastatic. Two-year overall survival was 18.5%, median overall survival was 15.2 months in the study population. PSA response was demonstrated in 59.2% of the patients. In multivariate analysis, the CRPC development time was found to be an independent prognostic factor both for overall survival and PSA response. Conclusion: DBC is still the main treatment option for CRPC patients for long term and successful outcomes.","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":null,"pages":null},"PeriodicalIF":0.1000,"publicationDate":"2017-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Efficiency of Docetaxel Chemotherapy on Castration Resistant Prostate Cancer: Singe Center Experience\",\"authors\":\"Evren Süer, N. Hamidi, M. Gökçe, S. Baltacı\",\"doi\":\"10.4274/UOB.821\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"77 ©Telif Hakkı 2017 Üroonkoloji Derneği / Üroonkoloji Bülteni Galenos Yayınevi tarafından basılmıştır Ya z›fl ma Ad re si/Ad dress for Cor res pon den ce: Dr. Nurullah Hamidi, Atatürk Eğitim ve Araştırma Hastanesi, Üroloji Kliniği, Ankara, Türkiye Tel.: +90 312 508 22 58 E-mail: dr.nhamidi86@gmail.com ORCID-ID: orcid.org/0000-0002-6825-1813 Ge liş Ta ri hi/Re cei ved: 06.02.2017 Ka bul Ta ri hi/Ac cep ted: 31.05.2017 Objective: Prostate cancer (PCa) is the second most commonly seen cancer type worldwide. Mortality due to PCa is mostly linked to the development of castration resistant PCa (CRPC). In these patients, the main treatment option is docetaxel based chemotherapy (DBC). In this study, we aimed to present our retrospective series. Materials and Methods: We retrospectively evaluated the patients who received DBC in our clinic between January 2004 and December 2015. Totally 162 patients who are histopathologically diagnosed with PCa, clinically and radiographically demonstrated metastasis and fit to European Association of Urology CRPC criteria were included to the study. DBC was given for one day for a 3-week period, with a dose of 75 mg/m2. Prostate specific antigen (PSA) response is evaluated for ≥50% decrease in the PSA level measured at the first day of the chemotherapy. Additionally, overall survival is evaluated. Results: The majority of the patients had high stage and high Gleason score PCa. Of them totally 76% were a primary metastatic. Two-year overall survival was 18.5%, median overall survival was 15.2 months in the study population. PSA response was demonstrated in 59.2% of the patients. In multivariate analysis, the CRPC development time was found to be an independent prognostic factor both for overall survival and PSA response. Conclusion: DBC is still the main treatment option for CRPC patients for long term and successful outcomes.\",\"PeriodicalId\":40816,\"journal\":{\"name\":\"Uroonkoloji Bulteni-Bulletin of Urooncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.1000,\"publicationDate\":\"2017-09-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Uroonkoloji Bulteni-Bulletin of Urooncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4274/UOB.821\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Uroonkoloji Bulteni-Bulletin of Urooncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/UOB.821","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

77©Telif hakkyi 2017 Üroonkoloji Derneği / Üroonkoloji b lteni Galenos Yayınevi tarafından basılmıştır Ya z›fl ma Ad re si/Ad dress for Cor res pon den ce: Nurullah Hamidi博士,atat rk Eğitim ve Araştırma Hastanesi, Üroloji Kliniği,土耳其安卡拉 rkiye电话:+90 312 508 22 58 E-mail: dr.nhamidi86@gmail.com orcidid - id: orcid.org/0000-0002-6825-1813 Ge liza Ta ri hi/接收日期:06.02.2017 Ka bul Ta ri hi/Ac接收日期:31.05.2017目的:前列腺癌(PCa)是全球第二常见的癌症类型。前列腺癌的死亡率主要与去势抵抗性前列腺癌(CRPC)的发展有关。在这些患者中,主要的治疗选择是基于多西他赛的化疗(DBC)。在这项研究中,我们旨在展示我们的回顾性系列。材料和方法:我们回顾性评估2004年1月至2015年12月在我诊所接受DBC治疗的患者。162例经组织病理学诊断为前列腺癌,临床和影像学证实转移,符合欧洲泌尿外科协会CRPC标准的患者被纳入研究。DBC给药1天,为期3周,剂量为75 mg/m2。在化疗第一天测量的PSA水平下降≥50%时评估前列腺特异性抗原(PSA)反应。此外,评估总生存期。结果:多数患者为高分期、高Gleason评分PCa。其中76%为原发性转移。研究人群的两年总生存率为18.5%,中位总生存率为15.2个月。59.2%的患者出现PSA应答。在多变量分析中,发现CRPC发展时间是总生存和PSA反应的独立预后因素。结论:DBC仍是CRPC患者长期有效的主要治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The Efficiency of Docetaxel Chemotherapy on Castration Resistant Prostate Cancer: Singe Center Experience
77 ©Telif Hakkı 2017 Üroonkoloji Derneği / Üroonkoloji Bülteni Galenos Yayınevi tarafından basılmıştır Ya z›fl ma Ad re si/Ad dress for Cor res pon den ce: Dr. Nurullah Hamidi, Atatürk Eğitim ve Araştırma Hastanesi, Üroloji Kliniği, Ankara, Türkiye Tel.: +90 312 508 22 58 E-mail: dr.nhamidi86@gmail.com ORCID-ID: orcid.org/0000-0002-6825-1813 Ge liş Ta ri hi/Re cei ved: 06.02.2017 Ka bul Ta ri hi/Ac cep ted: 31.05.2017 Objective: Prostate cancer (PCa) is the second most commonly seen cancer type worldwide. Mortality due to PCa is mostly linked to the development of castration resistant PCa (CRPC). In these patients, the main treatment option is docetaxel based chemotherapy (DBC). In this study, we aimed to present our retrospective series. Materials and Methods: We retrospectively evaluated the patients who received DBC in our clinic between January 2004 and December 2015. Totally 162 patients who are histopathologically diagnosed with PCa, clinically and radiographically demonstrated metastasis and fit to European Association of Urology CRPC criteria were included to the study. DBC was given for one day for a 3-week period, with a dose of 75 mg/m2. Prostate specific antigen (PSA) response is evaluated for ≥50% decrease in the PSA level measured at the first day of the chemotherapy. Additionally, overall survival is evaluated. Results: The majority of the patients had high stage and high Gleason score PCa. Of them totally 76% were a primary metastatic. Two-year overall survival was 18.5%, median overall survival was 15.2 months in the study population. PSA response was demonstrated in 59.2% of the patients. In multivariate analysis, the CRPC development time was found to be an independent prognostic factor both for overall survival and PSA response. Conclusion: DBC is still the main treatment option for CRPC patients for long term and successful outcomes.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
50.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信